Quantitative CT Analysis Using Functional Imaging is Superior in Describing Disease Progression in Idiopathic Pulmonary Fibrosis Compared to Forced Vital Capacity

Overview

Journal Respir Res

Specialty Pulmonary Medicine

Date 2018 Nov 8

PMID 30400950

Citations 18

Authors

J Clukers

M Lanclus

B Mignot

C Van Holsbeke

J Roseman

S Porter

E Gorina

E Kouchakji

K E Lipson

W De Backer

J De Backer

Affiliations

Soon will be listed here.

Abstract

Background: Idiopathic pulmonary fibrosis (IPF) is chronic fibrosing pneumonia with an unpredictable natural disease history. Functional respiratory imaging (FRI) has potential to better characterize this disease. The aim of this study was to identify FRI parameters, which predict FVC decline in patients with IPF.

Methods: An IPF-cohort (treated with pamrevlumab for 48 weeks) was retrospectively studied using FRI. Serial CT's were compared from 66 subjects. Post-hoc analysis was performed using FRI, FVC and mixed effects models.

Results: Lung volumes, determined by FRI, correlated with FVC (lower lung volumes with lower FVC) (R = 0.61, p < 0.001). A negative correlation was observed between specific image based airway radius (siRADaw) at total lung capacity (TLC) and FVC (R = 0.18, p < 0.001). Changes in FVC correlated significantly with changes in lung volumes (R = 0.18, p < 0.001) and siRADaw (R = 0.15, p = 0.002) at week 24 and 48, with siRADaw being more sensitive to change than FVC. Loss in lobe volumes (R = 0.33, p < 0.001), increasing fibrotic tissue (R = 0.33, p < 0.001) and airway radius (R = 0.28, p < 0.001) at TLC correlated with changes in FVC but these changes already occur in the lower lobes when FVC is still considered normal.

Conclusion: This study indicates that FRI is a superior tool than FVC in capturing of early and clinically relevant, disease progression in a regional manner.

Citing Articles

Development of a machine learning model in prediction of the rapid progression of interstitial lung disease in patients with idiopathic inflammatory myopathy.

Qiang Y, Wang H, Ni Y, Wang J, Liu A, Yang H Quant Imaging Med Surg. 2024; 14(12):9258-9275.

PMID: 39698644 PMC: 11652001. DOI: 10.21037/qims-24-595.

Lung cell transplantation for pulmonary fibrosis.

Milman Krentsis I, Zheng Y, Rosen C, Shin S, Blagdon C, Shoshan E Sci Adv. 2024; 10(34):eadk2524.

PMID: 39178253 PMC: 11343030. DOI: 10.1126/sciadv.adk2524.

From pixels to prognosis: unlocking the potential of deep learning in fibrotic lung disease imaging analysis.

de la Orden Kett Morais S, Felder F, Walsh S Br J Radiol. 2024; 97(1161):1517-1525.

PMID: 38781513 PMC: 11332672. DOI: 10.1093/bjr/tqae108.

Towards the adoption of quantitative computed tomography in the management of interstitial lung disease.

Walsh S, De Backer J, Prosch H, Langs G, Calandriello L, Cottin V Eur Respir Rev. 2024; 33(171).

PMID: 38537949 PMC: 10966471. DOI: 10.1183/16000617.0055-2023.

Exploring computer-based imaging analysis in interstitial lung disease: opportunities and challenges.

Felder F, Walsh S ERJ Open Res. 2023; 9(4).

PMID: 37404849 PMC: 10316044. DOI: 10.1183/23120541.00145-2023.

References

Raghu G, Mageto Y, Lockhart D, Schmidt R, Wood D, Godwin J . The accuracy of the clinical diagnosis of new-onset idiopathic pulmonary fibrosis and other interstitial lung disease: A prospective study. Chest. 1999; 116(5):1168-74. DOI: 10.1378/chest.116.5.1168. View

Kolb M, Collard H . Staging of idiopathic pulmonary fibrosis: past, present and future. Eur Respir Rev. 2014; 23(132):220-4. PMC: 9487566. DOI: 10.1183/09059180.00002114. View

Kolb M, Richeldi L, Behr J, Maher T, Tang W, Stowasser S . Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume. Thorax. 2016; 72(4):340-346. PMC: 5520269. DOI: 10.1136/thoraxjnl-2016-208710. View

Yoon R, Seo J, Kim N, Lee H, Lee S, Lee Y . Quantitative assessment of change in regional disease patterns on serial HRCT of fibrotic interstitial pneumonia with texture-based automated quantification system. Eur Radiol. 2012; 23(3):692-701. DOI: 10.1007/s00330-012-2634-8. View

Sumikawa H, Johkoh T, Colby T, Ichikado K, Suga M, Taniguchi H . Computed tomography findings in pathological usual interstitial pneumonia: relationship to survival. Am J Respir Crit Care Med. 2007; 177(4):433-9. DOI: 10.1164/rccm.200611-1696OC. View

Jacob J, Bartholmai B, Rajagopalan S, Kokosi M, Egashira R, Brun A . Serial automated quantitative CT analysis in idiopathic pulmonary fibrosis: functional correlations and comparison with changes in visual CT scores. Eur Radiol. 2017; 28(3):1318-1327. DOI: 10.1007/s00330-017-5053-z. View

Latsi P, du Bois R, Nicholson A, Colby T, Bisirtzoglou D, Nikolakopoulou A . Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med. 2003; 168(5):531-7. DOI: 10.1164/rccm.200210-1245OC. View

du Bois R, Weycker D, Albera C, Bradford W, Costabel U, Kartashov A . Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med. 2011; 184(12):1382-9. DOI: 10.1164/rccm.201105-0840OC. View

Raghu G, Wells A, Nicholson A, Richeldi L, Flaherty K, Le Maulf F . Effect of Nintedanib in Subgroups of Idiopathic Pulmonary Fibrosis by Diagnostic Criteria. Am J Respir Crit Care Med. 2016; 195(1):78-85. PMC: 5214917. DOI: 10.1164/rccm.201602-0402OC. View

10.

Jacob J, Bartholmai B, Rajagopalan S, Kokosi M, Nair A, Karwoski R . Automated Quantitative Computed Tomography Versus Visual Computed Tomography Scoring in Idiopathic Pulmonary Fibrosis: Validation Against Pulmonary Function. J Thorac Imaging. 2016; 31(5):304-11. DOI: 10.1097/RTI.0000000000000220. View

11.

King Jr T, Bradford W, Castro-Bernardini S, Fagan E, Glaspole I, Glassberg M . A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370(22):2083-92. DOI: 10.1056/NEJMoa1402582. View

12.

Albera C . Challenges in idiopathic pulmonary fibrosis trials: the point on end-points. Eur Respir Rev. 2011; 20(121):195-200. PMC: 9584112. DOI: 10.1183/09059180.00001711. View

13.

Selman M, Carrillo G, Estrada A, Mejia M, Becerril C, Cisneros J . Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern. PLoS One. 2007; 2(5):e482. PMC: 1868965. DOI: 10.1371/journal.pone.0000482. View

14.

Kim E, Elicker B, Maldonado F, Webb W, Ryu J, Van Uden J . Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J. 2009; 35(6):1322-8. DOI: 10.1183/09031936.00092309. View

15.

Richeldi L, Ryerson C, Lee J, Wolters P, Koth L, Ley B . Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis. Thorax. 2012; 67(5):407-11. DOI: 10.1136/thoraxjnl-2011-201184. View

16.

De Backer J, Van Holsbeke C, Vos W, Vinchurkar S, Dorinsky P, Rebello J . Assessment of lung deposition and analysis of the effect of fluticasone/salmeterol hydrofluoroalkane (HFA) pressurized metered dose inhaler (pMDI) in stable persistent asthma patients using functional respiratory imaging. Expert Rev Respir Med. 2016; 10(8):927-33. DOI: 10.1080/17476348.2016.1192464. View

17.

Park H, Song J, Lee S, Oh S, Kim N, Seo J . Texture-Based Automated Quantitative Assessment of Regional Patterns on Initial CT in Patients With Idiopathic Pulmonary Fibrosis: Relationship to Decline in Forced Vital Capacity. AJR Am J Roentgenol. 2016; 207(5):976-983. DOI: 10.2214/AJR.16.16054. View

18.

Lopes A, Capone D, Mogami R, Cunha D, de Melo P, Jansen J . [Correlation of tomographic findings with pulmonary function parameters in nonsmoking patients with idiopathic pulmonary fibrosis]. J Bras Pneumol. 2008; 33(6):671-8. DOI: 10.1590/s1806-37132007000600010. View

19.

Martinez F, Collard H, Pardo A, Raghu G, Richeldi L, Selman M . Idiopathic pulmonary fibrosis. Nat Rev Dis Primers. 2017; 3:17074. DOI: 10.1038/nrdp.2017.74. View

20.

De Backer J, Vos W, Vinchurkar S, Van Holsbeke C, Poli G, Claes R . The effects of extrafine beclometasone/formoterol (BDP/F) on lung function, dyspnea, hyperinflation, and airway geometry in COPD patients: novel insight using functional respiratory imaging. J Aerosol Med Pulm Drug Deliv. 2014; 28(2):88-99. DOI: 10.1089/jamp.2013.1064. View